Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering drug-responsive replication machinery for precise control of self-amplifying RNA.

Nature biomedical engineering·2026

Same author

Rapid boosting increases germinal center responses to sequential vaccines.

Nature immunology·2026

Same author

Atomic layer deposition for core-shell microparticle vaccines enabling programmable antigen delivery to lymph nodes enhance humoral immune responses.

bioRxiv : the preprint server for biology·2026

Same author

Heterologous betacoronavirus spike immunization in non-human primates elicits antibodies that neutralize both sarbeco- and merbecoviruses.

Cell reports·2026

Same author

Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design.

Science (New York, N.Y.)·2026

Same author

Vaccination generates broadly cross-neutralizing antibodies to the HIV Env apex.

Nature·2026

Same journal

A native sulfur deposit in Gale crater, Mars.

Science (New York, N.Y.)·2026

Same journal

Coordinated demise of harmful algal blooms.

Science (New York, N.Y.)·2026

Same journal

Genetic effects put into context.

Science (New York, N.Y.)·2026

Same journal

Bacteria share proteins to survive antibiotics.

Science (New York, N.Y.)·2026

Same journal

Impacts shaped Earth's first continents.

Science (New York, N.Y.)·2026

Same journal

Erratum for the Report "Covalently bonded single-molecule junctions with stable and reversible photoswitched conductivity" by C. Jia <i>et al</i>.

Science (New York, N.Y.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 9, 2026

Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance

Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance

Published on: December 13, 2015

Delivering a STING to tumors.

Rick Liao¹, Darrell J Irvine¹

¹Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA, USA.

Science (New York, N.Y.)

|May 7, 2026

Summary

This summary is machine-generated.

STING agonist nanoparticles effectively activate antitumor immunity in preclinical models. This approach shows promise for cancer immunotherapy development in both mice and rabbits.

More Related Videos

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Published on: October 10, 2025

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

Related Experiment Videos

Last Updated: May 9, 2026

Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance

Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance

Published on: December 13, 2015

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

Published on: October 10, 2025

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation

Published on: December 15, 2010

Area of Science:

Immunology
Nanotechnology
Oncology

Background:

The STING (stimulator of interferon genes) pathway is crucial for innate immune responses against tumors.
Developing effective delivery systems for STING agonists is essential for cancer immunotherapy.

Purpose of the Study:

To evaluate the efficacy of STING agonist nanoparticles in triggering antitumor immunity.
To assess the therapeutic potential of these nanoparticles in preclinical animal models.

Main Methods:

Formulation of STING agonist nanoparticles.
Administration of nanoparticles to tumor-bearing mice and rabbits.
Assessment of immune cell activation and tumor growth inhibition.

Main Results:

STING agonist nanoparticles successfully activated potent immune responses.
Significant inhibition of tumor growth was observed in treated animals.
The nanoparticles demonstrated favorable safety profiles in mice and rabbits.

Conclusions:

STING agonist nanoparticles represent a promising strategy for cancer immunotherapy.
This approach warrants further investigation for clinical translation.
Nanoparticle-based STING activation can overcome challenges in delivering immunomodulatory agents.